Drugs / 68Ga-FAPI-04

Trials 6 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 02 trials
Phase 0 NCT07132645 Sep 2025 → Sep 2027 expected neuroendocrine neoplasm University of Michigan Rogel Cancer Center Recruiting No outcome recorded
Phase 0 NCT04533828 Sep 2020 → Aug 2023 fibrotic liver disease First Affiliated Hospital of Fujian Medical University Unknown No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT05506566 May 2022 → May 2025 neoplasm First Affiliated Hospital of Fujian Medical University Unknown No outcome recorded
Phase not applicable3 trials
NCT07553741 Apr → Dec 2025 breast cancer Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Completed No outcome recorded
NCT05999227 Jun → Dec 2023 rectal cancer Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Unknown No outcome recorded
NCT06270394 Apr 2022 → Nov 2023 cancer The First Affiliated Hospital of Anhui Medical University Completed No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 6 sources stand behind the page.

FieldValueCited text
Known as 68Ga-FAPI-04 “Participants with various types of cancer will have PET imaging 50-100 minutes after injection of 68Ga-FAP-CHX and another agent (68Ga-FAPI-04 or 18F-FDG).” NCT05506566
4

“The scan is performed approximately 40 min after injection of 1.85-3.7 MBq 68Ga-FAPI-04 per kg body weight.” NCT06270394

NCT04533828

NCT07553741

NCT05999227

Known as Gallium Ga 68-DOTA-FAPI-04 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07132645
Modality Diagnostic / imaging agent “68Ga-FAPI-04 positron emission tomography/computed tomography (PET/CT)” NCT04533828
Route Intravenous “single intravenous injection of 68Ga-FAPI-04” NCT04533828